Your browser doesn't support javascript.
loading
Clinical and Dosimetric Risk Factors Associated With Radiation-Induced Lung Toxicities After Multiple Courses of Lung Stereotactic Body Radiation Therapy.
Li, Xingzhe; Yorke, Ellen; Jackson, Andrew; Yue, Yujuan; Simone, Charles B; Apte, Aditya P; Rimner, Andreas; Gomez, Daniel R; Shaverdian, Narek; Gelblum, Daphna Y; Wu, Abraham J; Shepherd, Annemarie F.
Afiliação
  • Li X; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yorke E; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas.
  • Jackson A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yue Y; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Simone CB; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Apte AP; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rimner A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gomez DR; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shaverdian N; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gelblum DY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wu AJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shepherd AF; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Adv Radiat Oncol ; 9(1): 101284, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38260213
ABSTRACT

Purpose:

Data are limited on radiation-induced lung toxicities (RILT) after multiple courses of lung stereotactic body radiation therapy (SBRT). We herein analyze a large cohort of patients to explore the clinical and dosimetric risk factors associated with RILT in such settings. Methods and Materials A single institutional database of patients treated with multiple courses of lung SBRT between January 2014 and December 2019 was analyzed. Grade 2 or higher (G2+) RILT after the last course of SBRT was the primary endpoint. Composite plans were generated with advanced algorithms including deformable registration and equivalent dose adjustment. Logistic regression analyses were performed to examine correlations between patient or treatment factors including dosimetry and G2+ RILT. Risk stratification of patients and lung constraints based on acceptable normal tissue complication probability were calculated based on risk factors identified.

Results:

Among 110 eligible patients (56 female and 54 male), there were 64 synchronous (58.2%; defined as 2 courses of SBRT delivered within 30 days) and 46 metachronous (41.8%) courses of SBRT. The composite median lung V20, lung V5, and mean lung dose were 9.9% (interquartile range [IQR], 7.3%-12.4%), 32.2% (IQR, 25.5%-40.1%), and 7.0 Gy (IQR, 5.5 Gy-8.6 Gy), respectively. With a median follow-up of 21.1 months, 30 patients (27.3%) experienced G2+ RILT. Five patients (4.5%) developed G3 RILT, and 1 patient (0.9%) developed G4 RILT, and no patients developed G5 RILT. On multivariable regression analysis, female sex (odds ratio [OR], 4.35; 95% CI, 1.49%-14.3%; P = .01), synchronous SBRT (OR, 8.78; 95% CI, 2.27%-47.8%; P = .004), prior G2+ RILT (OR, 29.8; 95% CI, 2.93%-437%; P = .007) and higher composite lung V20 (OR, 1.18; 95% CI, 1.02%-1.38%; P = .030) were associated with significantly higher likelihood of G2+ RILT.

Conclusions:

Our data suggest an acceptable incidence of G2+ RILT after multiple courses of lung SBRT. Female sex, synchronous SBRT, prior G2+ RILT, and higher composite lung V20 may be risk factors for G2+ RILT.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article